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Body fluid homeostasis is critical for the survival of living
organisms and hence is tightly controlled. From initial studies
on the effects of secretin (SCT) on renal water reabsorption in
the 1940s and recent investigations of its role in cardiovascular
and neuroendocrine functions, it has now become
increasingly clear that this peptide is an integral component
of the homeostatic processes that maintain body fluid
balance. This review, containing some of our recent findings
of centrally expressed SCT on water intake, focuses on
the actions of SCT in influencing the physiological,
neuroendocrine, and cardiovascular processes that
subserve body fluid homeostasis.
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The progression of life forms from the paleozoic oceans to
rivers and to different terrestrial eco-niches required the
coevolution of osmoregulatory mechanisms that defend body
cells from the changes in the osmotic pressure imposed by
the surrounding fluids. In terrestrial mammals, sophisticated
physiological, behavioral, and cardiovascular responses
evolved so as to ensure the constancy of milieu interieur.
The physiological approach comprises adjustments in the
renal handling of water and electrolytes, which is primarily
regulated by the antidiuretic hormone, vasopressin (Vp). The
behavioral approach consists of the regulation of water
and salt intake, which is mainly modulated by the dipsogen,
angiotensin II (ANGII). The cardiovascular approach
controls the volume and pressure of body fluid using
both the renin–ANG system and Vp. These osmoregulatory
responses arose from stimuli that activated groups of
specialized nerve cells which are capable of transducing
changes in plasma osmolality into electrical signals to
maintain fluid and electrolyte balance in our body.
In recent years, it has become evident that secretin (SCT),
the oldest known peptide hormone1 controlling pancreatic
secretion of bicarbonate ion, is actually expressed in those
osmoregulatory neurons and could regulate multiple
processes, including neuroendocrine, behavioral, and cardio-
vascular responses, that underlie body fluid homeostasis.
This review will center on the influence of SCT in these
processes at various tissues.
SECRETIN
SCT is a 27-residue peptide hormone with an amidated
carboxyl terminus. The peptide was discovered by Bayliss and
Starling in 19021 and has subsequently been isolated/cloned
from porcine,2 chicken,3 cow,4 human,5 dog,6 rat,7 rabbit,8
guinea pig,9 ovine,10 and mouse.11 The best known action
of SCT is its stimulatory effects on the exocrine secretion of
pancreas, whereas the physiology of this peptide is complex
exerting pleiotropic activities in many tissues.12 When
reviewing its function, SCT is depicted as a peptide that
controls directional fluxes of water and electrolytes across
the plasma membrane. It was found to exhibit nanomolar
potency in stimulating channel-mediated Cl efflux in the
lung,13 and evoke the translocation of aquaporin-1 (AQP1)
from intracellular compartments to the apical membrane for
the transepithelial movement of water into the ductal bile
lumen.14
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RENAL EFFECTS OF SCT
In the early 1930s, it became apparent that SCT could
modulate renal functions.15 Unfortunately, these investigations
bunged up, in part, because of the conflicting reports showing
diuretic and antidiuretic effects of SCT. A number of studies
monitoring the effects of SCT on renal water handling led to
the conclusion that SCT is a diuretic peptide.15–17 These
observations contrast with the findings by Charlton et al.,18
who showed an anti-diuretic function of SCT, with an effective
dose 50 at about 0.70 nmol/kg. Therefore, it is until the recent
usage of the SCT receptor (SCTR)-deficient mouse model19
that a role of SCT in the kidney was finally confirmed.
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Figure 1 | SCT and its receptor in the kidney. (a) Bright-field photomicrograph of mouse kidney sections labeled with rabbit anti-mouse
SCTR antibody raised in our laboratory (1:250). The specificity of this antibody was tested using sections obtained from SCTR/ mice.19
SCTR was shown to localize in almost every segment of the nephron. (b) Diagrammatic illustration of the functions of SCT in the renal
collecting duct tubules. SCT might be capable of inducing water reabsorption in renal collecting duct principal cells by binding to SCTR,
which is localized on the basolateral membranes of the cells.19 On binding to its receptor, SCT activates an AC-cAMP–PKA cascade, which
could then lead to an increase in AQP2 expression, probably via the subsequent phosphorylation of CREB and the docking of this factor
onto the CRE site of the AQP2 gene promoter. In addition, SCT also induces the trafficking of AQP2 from the IV to the apical membrane
of the collecting duct. This could allow water influx into the principal cells via AQP2 and water outflux from the cells via AQP3 and AQP4,
which are constitutively expressed on the basolateral membrane. It is therefore possible that SCT could enhance water reabsorption
from the collecting tubules. AC, adenylyl cyclase; AQP, aquaporin; cAMP, cyclic adenosine monophosphate; CRE, cAMP responsive element;
CREB, cAMP responsive element binding protein; GTP, guanosine triphosphate; IV, intracellular vesicles; PKA, protein kinase A; SCT, secretin;
SCTR, SCT receptor.
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SCTR is expressed throughout the kidney (Figure 1a). Its
serum concentration was found to increase significantly
in hemodialysis patients20 and in patients with chronic
renal failure21 in comparison with controls, indicating
that the peptide might be associated with clinical-patholo-
gical status of the kidney. Morphologically, SCTR-deficient
mice showed no growth abnormality, but their kidney/body
weight ratio was significantly higher than their normal
littermates.19 Besides, histological examination showed
that the kidneys of SCTR/ mice were abnormal, char-
acterized by increased mesangial area, enlarged urinary space,
and frequent tubular dilation and hypertrophy in the
collecting tubules of the medullary region.19 This suggested
that SCTR/ might have altered water absorption
and filtration processes. Consistent to this notion, apart
from the effects of SCT in increasing the renal blood flow,22
single-nephron glomerular filtration rate, and glomerular
plasma flow,23 the peptide could probably induce renal water
reabsorption in kidney tubules. In medullary tubules isolated
from the SCTRþ /þ mice and normal Wistar rat, SCT was
found to induce a dose-dependent increase in AQP2
expression on the plasma membrane and a dose-dependent
decrease in AQP2 expression in the intracellular vesicles.19,24
This induced translocation of AQP2 was found to be
mediated via a cyclic adenosine monophosphate/protein
kinase A-dependent pathway,24 and was found to be absent in
the medullary tubules isolated from SCTR/ mice,19 hence
indicating that SCT induces the movement of AQP2 on
binding with its receptor (Figure 1b). This latest finding is in
agreement with an early report from Charlton et al.,18 who
showed a reduction of urine output via the stimulation of
adenylate cyclase in the outer medulla of the kidney when
SCT was injected intravenously.
Apart from in vitro treatment of SCT to medullary
tubules, the movement and the expression of AQP2 were
also examined in vivo in dehydrated mice. It was found that
SCTR/ mice showed less movement of AQP2 to the plasma
membrane than the SCTRþ /þ mice,19 suggesting that there
was an altered AQP2 response during hyperosmolality.
As SCTR/ mice showed normal transcript levels of Vp
receptor in their kidney, and slightly higher serum Vp levels
as well as hypothalamic Vp transcript levels (1.54-fold±0.19-
fold; Po0.05; n¼ 20) when compared with their wild-type
littermates,19 these data collectively suggested that SCT has a
Vp-independent role in the expression and movement of
AQP2s in the kidney, and hence were consistent with the
finding by Charlton et al.,18 who reported that the
antidiuretic effect of SCTwas as potent as Vp in homozygous
Vp-deficient Brattleboro rats. Taken together, these data
provided a plausible explanation for the underlying causes of
polydipsia and polyuria phenotypes observed in SCTR/
mice. Besides, these data could also be of great interest to
the nephrogenic diabetic insipidus community as it shows a
direction of study for developing therapies to treat nephro-
genic diabetic insipidus that are independent of the Vp
pathway.
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Figure 2 |Cellular distribution of SCT and SCTR in the central
osmoregulatory regions. (a) SCT and its receptor were
colocalized with Vp in the hypothalamic SON and PVN. The
antibodies employed were rabbit anti-SCT (1:250 dilution; Phoenix
Pharmaceuticals, Burlingame, CA), rabbit anti-SCTR (1:200 dilution;
Chu et al.19), goat anti-Vp (1:400 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA), Alexa Fluor 594 donkey anti-goat
IgG (1:500 dilution; Molecular Probes, Invitrogen, Carlsbad, CA),
and Alexa Fluor 488 chicken anti-rabbit IgG (1:500 dilution;
Molecular Probes. (b) Photographs of SFO section stained with
antiserum against SCT and SCTR. Both SCT and its receptor were
shown to be highly expressed within the SFO. Controls (c) were
performed by liquid-phase preabsorption of the antiserum with
either 0.1mM rat secretin or synthetic mouse secretin receptor
peptide (R-A-E-C-L-R-E-L-S-E-E-K-K, which is present in the mouse
secretin receptor) for 3 h at room temperature before incubating
with the sections. Bar¼ 6 mm. Ab, antibody; IgG, immunoglobulin
G; PVN, paraventricular; Rb, rabbit; paraventricular; SCT, secretin;
SCTR, SCT receptor; SFO, subfornical organ; SON, supraoptic; Vp,
vasopressin.
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NEUROENDOCRINE EFFECTS OF SECRETIN
Magnocellular neurons of the hypothalamic supraoptic
and paraventricular nuclei are integral component of the
hypothalamic–neurohypophysial system that is crucially
involved in the regulation of body fluid and electrolyte
homeostasis. Vp released from the posterior pituitary
regulates renal water reabsorption and thereby controlling
the rate of water loss from our body. In the kidney, the
capability of Vp in maintaining body fluids depends on its
action on a water channel, AQP2, which is largely responsible
for renal water reabsorption and hence the urine concentrat-
ing ability. This is achieved by the cyclic adenosine
monophosphate/protein kinase A-dependent insertion of
AQP2 onto the apical membrane of the collecting duct
principal cells, wherein it functions as a hydrophilic pore to
allow initial water movement from lumen to cytoplasm, and
then subsequently via AQP3 and AQP4 located on the
basolateral membrane to plasma. Evidence from both in vitro
and in vivo studies, however, have indicated the presence of
Vp-independent mechanisms regulating this renal water
reabsorption process. The first piece of evidence came from
using Vp-deficient Brattleboro rats. Li et al.25 showed that
hyperosmolality in these animals could increase AQP2
expression and trafficking, as well as urinary osmolality,
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Figure 3 |Centrally expressed SCT is a dipsogenic agent. (a) ICV-SCT (30 mM) into the lateral ventricular induced Fos-immunoreactivities
in the SFO when compared with ICV injection of isotonic saline (ICV-PBS). (b) Centrally expressed SCT, but not circulating
SCT, induces drinking behavior. (A) Centrally injected SCT dose-dependently increase water intake and urine output. Data points are
the mean fold±s.e.m. of values obtained in 15–20 rats per group. *Po0.05 and **Po0.01 versus PBS-treatment group. (B) Peripheral
injection of SCT through osmotic minipump was not capable of increasing water intake in rats compared with those injected with isotonic
saline (IV-PBS). ANGII, a dipsogenic agent when intravenously injected into the rat, was used as an internal control. ANGII, angiotensin II;
ICV, intracerebroventricular; IV, intracellular vesicles; PBS, phosphate-buffered saline; SCT, secretin.
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indicating the presence of mechanisms independent of Vp in
stimulating AQP2 expression and translocation. Another
piece of evidence came from the observation that 10 pM Vp,
which is the highest plasma concentration of Vp found
in severe dehydration, could only increase osmotic water
permeability to 44% of its maximal.26 Other factors,
therefore, could boost osmotic water permeability to levels
higher than those by Vp alone. Consistent with this notion,
Bauman27 observed a reduction in the osmotic gradient
along the length of the papilla in hypophysectomized rats,
and this reduction could not be restored back to normal
upon exogenous Vp treatment. This indicates the limited
effectiveness of Vp in the absence of other pituitary
hormone(s) which is/are likely required for developing the
osmotic gradient.
SCT has recently been identified to potentially regulate
renal water reabsorption, and interestingly, this peptide
hormone has a much higher expression in the pituitary
when compared with the brain.28 O’Donohue et al.29
detected B17 times higher amount of SCT in the pituitary
gland than that in the cerebral cortex, whereas Charlton
et al.30 revealed that within the pituitary, concentration of
SCT in the neurointermediate lobe was about 45-fold higher
than that observed in the anterior lobe. Consistent with
this, a recent study demonstrated abundant levels of SCT
immunoreactivities in the Herring bodies of the posterior
pituitary,31 indicating the potential of SCT as a neuro-
secretory hormone. This is supported by peptide release
studies, in which exposure of pituitary explants to a depolari-
zing stimulation of 80mM Kþ evoked SCT release in a
tetrodotoxin-dependent manner.31 Besides, an increase in the
plasma SCT level was also found during water deprivation in
normal rats but not hypophysectomized rats.31 These support
the idea that SCT is a neurosecretory factor being release
from the posterior pituitary into the circulation during
hyperosmolality. It then functions in the kidney in a similar
manner as Vp to stimulate the translocation of AQP2, and
hence a possible role on renal water reabsorption.
Apart from releasing into the systemic circulation, SCT
can also be released locally within the central nervous
system,32,33 indicating its role as a neuropeptide. Within the
brain, SCTRs were localized in areas including the circum-
ventricular organs and the Vpergic neurons within paraven-
tricular and supraoptic (Figure 2).31 These nuclei are the
primary brain sites that are engaged in the defense of fluid
perturbation, thus providing anatomical evidence to support
the functional role of SCT in modulating neuroendocrine
responses to osmotic stimuli. Consistent to this notion, we
had previously shown that (1) transcript levels of SCT
and SCTR were both increased in the hypothalamus during
water deprivation,31 and (2) SCT could be released from the
hypothalamic explants under depolarizing stimulation.32 In
addition, intracerebroventricular injection of SCTwas able to
induce c-fos expression in Vp-expressing magnocellular
neurons in paraventricular and supraoptic, in which it
specifically augments Vp expression and secretion from the
axonal terminals into the systemic circulation.31 All these
observations implicate a functional role of SCT as one of
the fluid regulating hormones in our bodies.
EFFECTS OF SCT ON DRINKING BEHAVIOR
The function of SCT in changing behaviors associated
with fluid balance is suggested by the presence of SCT and
SCTR in the subfornical organ (SFO; Figure 2b), a forebrain
circumventricular region that is known to be important
in ANGII-induced water intake. Intracerebroventricular
SCT could induce Fos-immunoreactivities in this region
(Figure 3a), showing that SFO is responsive to SCT.
Moreover, intracerebroventricular SCT-injected rats were
found to drink more water and hence produce more urine
than rats injected with the saline control (Figure 3A); SCT is
therefore a putative dipsogenic agent. Peripherally injected
SCT, however, was incapable of inducing the water drinking
behavior (Figure 3B). Our data therefore shows that only
centrally injected SCT, but not circulating SCT, could
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Figure 4 | Secretin is possibly a mediator of ANGII action.
(a) Centrally, but not peripherally, injected ANGII induced central
SCT expression. Results are presented in mean fold
changes±s.e.m. (n¼ 5). *Po0.05 versus PBS-treatment group.
(b) Centrally injected ANG triggers SCT release into peripheral
circulation. Blood samples (150ml) were collected every 5min from
the jugular vein from 5min before to 30min (5-min interval) after
ICV infusion of 5mg ANG. The results are presented in mean fold
changes±s.e.m. relative to PBS-infused basal level of SCT in the
plasma (0.099±0.005ng/ml). *Po0.05 and **Po0.01.
ANG; angiotensin; ICV, intracerebroventricular; IV, intracellular
vesicles; PBS, phosphate-buffered saline; SCT, secretin.
284 Kidney International (2011) 79, 280–287
min i rev iew JYS Chu et al.: Secretin and water homeostasis
significantly change water intake and urinary output over
a 24-h period.
The forebrain SFO is an upstream component of the
central ANGII pathway leading to water intake and Vp
secretion from the neurohypophyseal system.34 SCT induc-
tion of Fos immunoreactivities in SFO therefore raises the
possibility of the interaction between ANGII and SCT at SFO.
In fact, centrally injected ANGII was able to increase plasma
SCT level as well as its expression in central (Figure 4). It is
therefore possible that SCT mediates the central effects of
ANGII on water ingestion as well as Vp secretion from the
posterior pituitary.
CARDIOVASCULAR EFFECTS OF SECRETIN
Changes in the extracellular volume (blood volume) and
pressure are detected by baroreceptors, and information are
sent via the IXth and Xth cranial nerves primarily to the
nucleus tractus solitarius (NTS), which is a region essential
for the regulation of cardiovascular function. The notion that
SCT can directly influence central processing of information
related to blood pressure via NTS is supported by the fact
that (i) 125I-SCT binding sites were detected in NTS35;
(ii) intravenous injection of SCTwas found to stimulate c-fos
expression in NTS36; and (iii) SCT was found to directly
activate NTS neurons via the stimulation of a nonselective
cationic conductance.35 Consistently, there are findings
showing that intravenous injection of SCT causes a
significant fall of arterial blood pressure,2 and that the heart
membranes of Lyon strain of hypertensive rats have a 30–35%
decrease of SCT-stimulated adenylate cyclase activity
when compared with Lyon normotensive rats and Lyon
low-blood-pressure rats.37 These suggested a possible role of
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Figure 5 |Diagrammatic illustration of the functions of SCT in SFO and hypothalamus. In the SFO, SCT-stimulated c-fos expression is
believed to function via the binding of SCT onto its receptor, hence triggering the activation of AC that increases the intracellular
cAMP level. Activated PKA could then induce the phosphorylation of CRE binding protein (CREB), and hence the transcription of c-fos
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activating transcription factor proteins, to the stimulation of Fos/Jun family of transcription factors. Subsequent dimerization of the product
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SCT as a vasodilator. One interesting point to note is, during
SCT-induced mesenteric vasodilation, a significant redistribu-
tion of blood was observed,38 that is, SCT may affect blood
flow distribution in certain peripheral organs. In fact, SCT has
previously been found to cause a preponderance of flow of
cardiac output to the renal circulation among renal, carotid,
femoral, and the superior mesenteric arteries39 In dogs with
an acute left ventricular failure, although, SCT injection
restores blood flow to a level similar as in healthy subjects by
directing cardiac output to all the investigated arteries.40 As
injection of pharmacological doses of SCT in patients with
reduced cardiac function could augment left ventricular
performance by arteriolar dilation and its positive inotropic
effect,41 SCT may therefore regulate blood flow distribution.
Taken together, as precise control of body fluid homeostasis
requires mechanisms that maintain overall water and sodium
balance as well as appropriate regional and compartmental
distributions of these substances, that is, consistency in blood
volume and pressure, SCT might also be involved in the
toning of cardiovascular response when there are changes in
body fluid and volume. However, further studies are needed
to confirm a role of the peptide in this aspect.
CONCLUSION AND FUTURE PRESPECTIVE
The objective of this review is to summarize findings and to
provide an overview on how SCT influences particular
compensatory responses during body fluid challenges. In the
central nervous system, the peptide stimulates drinking
behavior and the release of Vp into the circulation (Figure 5),
whereas in the renal system, it activates AQP2 expression and
trafficking in the collecting tubules, hence suggesting its
potential role on renal water retention. Clearly, our under-
standing on the detail pathways and mechanisms involved in
SCT-regulated body fluid balance, the neuronal regions
participated in SCT-induced responses, and the cardiovas-
cular role of this peptide during changes in body fluid are not
completely understood. Nevertheless, with the generation
and functional characterization of transgenic mouse models,
we could have experimentally accessible system for re-
assessing multiple aspects of this peptide–ligand pair,
particularly their role in sodium homeostasis and the
cardiovascular system. Alternatively, the generation of
transgenic mouse models could also provide proof-of-
principle insight for the development of new therapeutic
strategies for certain disorders. For example, observation of
the pathological symptoms that are characteristics of
nephrogenic diabetic insipidus in SCTR/ mice has
suggested the possibility that SCT could serve as a potential
candidate in treating X-linked nephrogenic diabetic insipidus
with defective V2R signaling. Along with reported effects of
this peptide on insulin secretion,42 it is also believed that
alteration in the synthesis and/or secretion of SCT might
probably contribute to renal and metabolic perturbations
observed in diabetes as well as type D syndrome of
inappropriate anti-diuretic hormone, in which no demon-
strable abnormality in the osmoregulation of Vp was
reported. Therefore, further understanding of the roles of
SCT in body fluid balance should provide direction for future
programs aimed at developing SCT/SCT agonists/SCTR
antagonists for the prevention and/or therapeutic interven-
tion of disorders in body water homeostasis. A widespread
use in disease treatment, however, requires well-designed
studies that lead us to a more detail understanding regarding
their safety for repeated administration, as well as their
dosage and side effects.
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